Authors
Coward, JKulbe, H
Chakravarty, P
Leader, D
Vassileva, V
Leinster, D A
Thompson, R
Schioppa, T
Nemeth, J
Vermeulen, J
Singh, N
Avril, N
Cummings, Jeffrey
Rexhepaj, E
Jirström, K
Gallagher, W M
Brennan, D J
McNeish, I A
Balkwill, F R
Affiliation
Barts Cancer Institute, Queen Mary University of London, UK.Issue Date
2011-09-15
Metadata
Show full item recordAbstract
We investigated whether inhibition of interleukin 6 (IL-6) has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network.Citation
Interleukin-6 as a therapeutic target in human ovarian cancer. 2011, 17 (18):6083-96 Clin. Cancer Res.Journal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-11-0945PubMed ID
21795409Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-11-0945
Scopus Count
Collections
Related articles
- Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
- Authors: Guo Y, Nemeth J, O'Brien C, Susa M, Liu X, Zhang Z, Choy E, Mankin H, Hornicek F, Duan Z
- Issue date: 2010 Dec 1
- IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
- Authors: Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML, Wei LH
- Issue date: 2011 Jan 15
- IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
- Authors: Zhu X, Shen H, Yin X, Long L, Chen X, Feng F, Liu Y, Zhao P, Xu Y, Li M, Xu W, Li Y
- Issue date: 2017 Jun 13
- [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
- Authors: Guo YQ, Lu P, Duan ZF, Zhang Z
- Issue date: 2010 Nov
- MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
- Authors: Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, Tung YC, Hsu HL
- Issue date: 2019 Mar 18